Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Hansen Scott G."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-19 z 19
    Tytuł:
    Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.
    Autorzy:
    Chang XL; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Reed JS; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Webb GM; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Wu HL; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Le J; Quest Clinical Research, San Francisco, California, United States of America.
    Bateman KB; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Greene JM; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Pessoa C; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Waytashek C; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Weber WC; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Hwang J; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Fischer M; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Moats C; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Shiel O; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Bochart RM; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Crank H; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Siess D; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Giobbi T; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Torgerson J; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Agnor R; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Gao L; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Dhody K; Amarex Clinical Research LLC, Germantown, Maryland, United States of America.
    Lalezari JP; Quest Clinical Research, San Francisco, California, United States of America.
    Bandar IS; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America.
    Carnate AM; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America.
    Pang AS; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America.
    Corley MJ; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America.
    Kelly S; CytoDyn Inc., Vancouver, Washington, United States of America.
    Pourhassan N; CytoDyn Inc., Vancouver, Washington, United States of America.
    Smedley J; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Bimber BN; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Hansen SG; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
    Ndhlovu LC; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America.
    Sacha JB; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2022 Mar 31; Vol. 18 (3), pp. e1010396. Date of Electronic Publication: 2022 Mar 31 (Print Publication: 2022).
    Typ publikacji:
    Clinical Study; Journal Article
    MeSH Terms:
    Simian Immunodeficiency Virus*
    Animals ; Antibodies, Monoclonal, Humanized/pharmacology ; HIV Antibodies ; Humans ; Macaca mulatta ; Receptors, CCR5
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.
    Autorzy:
    Barrenäs F; Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
    Hansen SG; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Law L; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Driscoll C; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Green RR; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Smith E; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Chang J; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Golez I; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Urion T; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Peng X; Department of Molecular Biomedical Sciences and Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, United States of America.
    Whitmore L; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Newhouse D; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Hughes CM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Morrow D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Randall KT; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Selseth AN; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Ford JC; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Gilbride RM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Randall BE; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Ainslie E; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Oswald K; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Shoemaker R; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Fast R; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Bosche WJ; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Axthelm MK; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Fukazawa Y; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Pavlakis GN; Human Retrovirus Section, Vaccine Branch, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
    Felber BK; Human Retrovirus Pathogenesis Section, Vaccine Branch, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
    Fourati S; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America.
    Sekaly RP; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America.
    Lifson JD; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Komorowski J; Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
    Kosmider E; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Shao D; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Song W; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Edlefsen PT; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Picker LJ; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Gale M Jr; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2021 Jul 06; Vol. 17 (7), pp. e1009278. Date of Electronic Publication: 2021 Jul 06 (Print Publication: 2021).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    CD8-Positive T-Lymphocytes/*immunology
    Interleukin-15/*immunology
    SAIDS Vaccines/*immunology
    Simian Immunodeficiency Virus/*immunology
    Animals ; Cytomegalovirus ; Female ; Genetic Vectors ; Macaca mulatta ; Male ; Simian Acquired Immunodeficiency Syndrome/prevention & control
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques.
    Autorzy:
    Bochart RM; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Busman-Sahay K; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Bondoc S; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Morrow DW; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Ortiz AM; Barrier Immunity Section, Lab of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United State of America.
    Fennessey CM; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Fischer MB; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Shiel O; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Swanson T; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Shriver-Munsch CM; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Crank HB; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Armantrout KM; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Barber-Axthelm AM; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Langner C; Barrier Immunity Section, Lab of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United State of America.
    Moats CR; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Labriola CS; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    MacAllister R; Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Axthelm MK; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Brenchley JM; Barrier Immunity Section, Lab of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United State of America.
    Keele BF; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Estes JD; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Hansen SG; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Smedley JV; Infectious Disease Resource, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.; Division of Pathobiology and Immunology, Oregon National Primate Research Center, and Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2021 May 10; Vol. 17 (5), pp. e1009565. Date of Electronic Publication: 2021 May 10 (Print Publication: 2021).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Inflammation/*therapy
    Microbiota/*drug effects
    Simian Acquired Immunodeficiency Syndrome/*therapy
    Simian Immunodeficiency Virus/*immunology
    Adaptive Immunity ; Animals ; B-Lymphocytes ; CD4-Positive T-Lymphocytes ; Cell Proliferation ; Combined Modality Therapy ; Gastrointestinal Tract/immunology ; Gastrointestinal Tract/microbiology ; Humans ; Immunity, Innate ; Intestinal Mucosa ; Lymph Nodes ; Macaca mulatta ; Male ; Monocytes ; Simian Acquired Immunodeficiency Syndrome/immunology ; Simian Acquired Immunodeficiency Syndrome/virology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.
    Autorzy:
    Verweij MC; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Hansen SG; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Iyer R; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    John N; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Malouli D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Morrow D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Scholz I; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Womack J; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Abdulhaqq S; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Gilbride RM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Hughes CM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Ventura AB; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Ford JC; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Selseth AN; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Oswald K; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
    Shoemaker R; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
    Berkemeier B; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
    Bosche WJ; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
    Hull M; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
    Shao J; Population Sciences and Computational Biology Programs, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
    Sacha JB; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Axthelm MK; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Edlefsen PT; Population Sciences and Computational Biology Programs, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
    Lifson JD; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
    Picker LJ; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. .
    Früh K; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. .
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2021 Apr 30; Vol. 372 (6541). Date of Electronic Publication: 2021 Mar 25.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    CD8-Positive T-Lymphocytes/*immunology
    Cytomegalovirus/*metabolism
    Genetic Vectors/*metabolism
    Histocompatibility Antigens Class I/*metabolism
    Peptide Fragments/*metabolism
    SAIDS Vaccines/*immunology
    Animals ; Cell Line ; Cytomegalovirus/genetics ; Epitopes, T-Lymphocyte/immunology ; Fibroblasts/metabolism ; Genetic Vectors/genetics ; Histocompatibility Antigens Class I/genetics ; Ligands ; Macaca mulatta ; Peptide Fragments/genetics ; Protein Transport ; Simian Immunodeficiency Virus ; HLA-E Antigens
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    In vitro and in vivo characterization of a recombinant rhesus cytomegalovirus containing a complete genome.
    Autorzy:
    Taher H; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Mahyari E; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Kreklywich C; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Uebelhoer LS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    McArdle MR; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Moström MJ; Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America.
    Bhusari A; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Nekorchuk M; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    E X; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
    Whitmer T; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Scheef EA; Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America.
    Sprehe LM; Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America.
    Roberts DL; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
    Hughes CM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Jackson KA; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Selseth AN; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Ventura AB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Cleveland-Rubeor HC; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Yue Y; Center for Comparative Medicine and Department of Medical Pathology, University of California, Davis, California, United States of America.
    Schmidt KA; Center for Comparative Medicine and Department of Medical Pathology, University of California, Davis, California, United States of America.
    Shao J; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Edlefsen PT; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Smedley J; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Kowalik TF; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
    Stanton RJ; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
    Axthelm MK; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Estes JD; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Kaur A; Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America.
    Barry PA; Center for Comparative Medicine and Department of Medical Pathology, University of California, Davis, California, United States of America.
    Bimber BN; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Picker LJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Streblow DN; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Früh K; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Malouli D; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2020 Nov 24; Vol. 16 (11), pp. e1008666. Date of Electronic Publication: 2020 Nov 24 (Print Publication: 2020).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Viremia*
    Cytomegalovirus/*genetics
    Cytomegalovirus Infections/*virology
    Genome, Viral/*genetics
    Animals ; Cell Line ; Chromosomes, Artificial, Bacterial ; Cytomegalovirus/pathogenicity ; DNA, Recombinant ; Disease Models, Animal ; Female ; Fibroblasts/virology ; Humans ; Macaca mulatta ; Male ; Mutation ; Open Reading Frames/genetics ; Phylogeny ; Species Specificity
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Characterization of a live-attenuated HCMV-based vaccine platform.
    Autorzy:
    Caposio P; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    van den Worm S; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.; Batavia Biosciences B.V., Zernikedreef 16, 2333 CL, Leiden, Netherlands.
    Crawford L; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Perez W; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Kreklywich C; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Gilbride RM; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Hughes CM; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Ventura AB; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Ratts R; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.; Vir Biotechnology, 4640, SW Macadam Avenue, Portland, OR, 97239, USA.
    Marshall EE; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.; Vir Biotechnology, 4640, SW Macadam Avenue, Portland, OR, 97239, USA.
    Malouli D; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Axthelm MK; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Streblow D; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Nelson JA; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Picker LJ; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA.
    Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA. .
    Früh K; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, 97006, USA. .
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2019 Dec 17; Vol. 9 (1), pp. 19236. Date of Electronic Publication: 2019 Dec 17.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Cytomegalovirus*/genetics
    Cytomegalovirus*/immunology
    Cytomegalovirus Infections*/genetics
    Cytomegalovirus Infections*/immunology
    Cytomegalovirus Infections*/prevention & control
    Cytomegalovirus Vaccines*/genetics
    Cytomegalovirus Vaccines*/immunology
    Animals ; Cell Line, Tumor ; Human Umbilical Vein Endothelial Cells ; Humans ; Mice ; Mice, Inbred NOD ; Vaccines, Attenuated/genetics ; Vaccines, Attenuated/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Interferon-Gamma test for the detection of Mycobacterium tuberculosis complex infection in Macaca mulatta and other non-human primates.
    Autorzy:
    Yee JL; California National Primate Research Center, University of California, Davis, California.
    Prongay K; Oregon National Primate Research Center, Oregon Health Sciences University, Beaverton, Oregon.
    Miles B; Oregon National Primate Research Center, Oregon Health Sciences University, Beaverton, Oregon.
    Smedley J; Oregon National Primate Research Center, Oregon Health Sciences University, Beaverton, Oregon.
    Hansen SG; Oregon National Primate Research Center, Oregon Health Sciences University, Beaverton, Oregon.
    Axthelm MK; Oregon National Primate Research Center, Oregon Health Sciences University, Beaverton, Oregon.
    Ardeshir A; California National Primate Research Center, University of California, Davis, California.
    Van Rompay KKA; California National Primate Research Center, University of California, Davis, California.
    Timmel G; Oregon National Primate Research Center, Oregon Health Sciences University, Beaverton, Oregon.
    Roberts JA; California National Primate Research Center, University of California, Davis, California.
    Pokaż więcej
    Źródło:
    Journal of medical primatology [J Med Primatol] 2019 Aug; Vol. 48 (4), pp. 260-263. Date of Electronic Publication: 2019 May 06.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Macaca mulatta*
    Enzyme-Linked Immunosorbent Assay/*veterinary
    Interferon-gamma Release Tests/*veterinary
    Monkey Diseases/*diagnosis
    Mycobacterium tuberculosis/*isolation & purification
    Tuberculosis/*diagnosis
    Animals ; Enzyme-Linked Immunosorbent Assay/methods ; Interferon-gamma Release Tests/methods
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge.
    Autorzy:
    Hansen SG; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.; Oregon Health & Science University, Oregon National Primate Research Center, Beaverton, OR, United States of America.
    Womack J; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.
    Scholz I; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.
    Renner A; US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD, United States of America.
    Edgel KA; US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD, United States of America.
    Xu G; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.
    Ford JC; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.
    Grey M; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.
    St Laurent B; National Institutes of Health, Laboratory of Malaria and Vector Research, Malaria Pathogenesis and Human Immunity Unit, Rockville, MD, United States of America.
    Turner JM; Oregon Health & Science University, Oregon National Primate Research Center, Beaverton, OR, United States of America.
    Planer S; Oregon Health & Science University, Oregon National Primate Research Center, Beaverton, OR, United States of America.
    Legasse AW; Oregon Health & Science University, Oregon National Primate Research Center, Beaverton, OR, United States of America.
    Richie TL; US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD, United States of America.
    Aguiar JC; US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD, United States of America.
    Axthelm MK; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.; Oregon Health & Science University, Oregon National Primate Research Center, Beaverton, OR, United States of America.
    Villasante ED; US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD, United States of America.
    Weiss W; US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD, United States of America.
    Edlefsen PT; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
    Picker LJ; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.; Oregon Health & Science University, Oregon National Primate Research Center, Beaverton, OR, United States of America.
    Früh K; Oregon Health & Science University, Vaccine & Gene Therapy Institute, Beaverton, OR, United States of America.; Oregon Health & Science University, Oregon National Primate Research Center, Beaverton, OR, United States of America.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2019 Jan 23; Vol. 14 (1), pp. e0210252. Date of Electronic Publication: 2019 Jan 23 (Print Publication: 2019).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Antigens, Protozoan/*immunology
    Cytomegalovirus/*genetics
    Malaria/*immunology
    Malaria Vaccines/*immunology
    Parasitemia/*immunology
    Plasmodium knowlesi/*immunology
    Sporozoites/*immunology
    Animals ; Anopheles/immunology ; Anopheles/parasitology ; Female ; Genetic Vectors/administration & dosage ; Immunologic Memory ; Liver/immunology ; Liver/parasitology ; Macaca mulatta ; Malaria/blood ; Malaria/parasitology ; Malaria/prevention & control ; Male ; Parasitemia/blood ; Parasitemia/parasitology ; Parasitemia/prevention & control ; Plasmodium knowlesi/genetics ; Protozoan Proteins/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/parasitology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Natural Killer Cell Evasion Is Essential for Infection by Rhesus Cytomegalovirus.
    Autorzy:
    Sturgill ER; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Malouli D; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Hansen SG; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Burwitz BJ; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Seo S; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Schneider CL; Department of Life Sciences, Carroll University, Waukesha, Wisconsin, United States of America.
    Womack JL; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Verweij MC; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Ventura AB; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Bhusari A; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Jeffries KM; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Legasse AW; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Axthelm MK; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Hudson AW; Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
    Sacha JB; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Picker LJ; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Früh K; Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2016 Aug 31; Vol. 12 (8), pp. e1005868. Date of Electronic Publication: 2016 Aug 31 (Print Publication: 2016).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Immune Evasion*
    Lymphocyte Activation*
    Cytomegalovirus/*immunology
    Cytomegalovirus Infections/*immunology
    Killer Cells, Natural/*immunology
    Animals ; Humans ; K562 Cells ; Macaca fascicularis ; Membrane Glycoproteins/immunology ; NK Cell Lectin-Like Receptor Subfamily K/immunology ; Viral Proteins/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E.
    Autorzy:
    Hansen SG; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Wu HL; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Burwitz BJ; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Hughes CM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Hammond KB; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Ventura AB; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Reed JS; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Gilbride RM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Ainslie E; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Morrow DW; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Ford JC; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Selseth AN; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Pathak R; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Malouli D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Legasse AW; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Axthelm MK; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Nelson JA; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Gillespie GM; Nuffield Department of Medicine, University of Oxford, Oxford OX37FZ, UK.
    Walters LC; Nuffield Department of Medicine, University of Oxford, Oxford OX37FZ, UK.
    Brackenridge S; Nuffield Department of Medicine, University of Oxford, Oxford OX37FZ, UK.
    Sharpe HR; Nuffield Department of Medicine, University of Oxford, Oxford OX37FZ, UK.
    López CA; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
    Früh K; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Korber BT; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA. The New Mexico Consortium, Los Alamos, NM 87545, USA.
    McMichael AJ; Nuffield Department of Medicine, University of Oxford, Oxford OX37FZ, UK.
    Gnanakaran S; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
    Sacha JB; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Picker LJ; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2016 Feb 12; Vol. 351 (6274), pp. 714-20. Date of Electronic Publication: 2016 Jan 21.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    CD8-Positive T-Lymphocytes/*immunology
    Cytomegalovirus/*immunology
    Epitopes, T-Lymphocyte/*immunology
    Histocompatibility Antigens Class I/*immunology
    Simian Immunodeficiency Virus/*immunology
    Animals ; Antigen Presentation ; Antigenic Variation ; Cytomegalovirus/genetics ; Epitopes, T-Lymphocyte/chemistry ; Genetic Vectors/genetics ; Genetic Vectors/immunology ; Histocompatibility Antigens Class I/chemistry ; Host-Pathogen Interactions/immunology ; Immune Evasion ; Killer Cells, Natural/immunology ; Macaca mulatta ; Protein Structure, Secondary ; Vaccination
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
    Autorzy:
    Chew GM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Fujita T; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Webb GM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Burwitz BJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Wu HL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Reed JS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Hammond KB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Clayton KL; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
    Ishii N; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Abdel-Mohsen M; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Liegler T; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Mitchell BI; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Hecht FM; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Ostrowski M; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
    Shikuma CM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Maurer M; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
    Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
    Deeks SG; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Sacha JB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Ndhlovu LC; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2016 Jan 07; Vol. 12 (1), pp. e1005349. Date of Electronic Publication: 2016 Jan 07 (Print Publication: 2016).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    CD4-Positive T-Lymphocytes/*immunology
    CD8-Positive T-Lymphocytes/*immunology
    HIV Infections/*immunology
    Receptors, Immunologic/*immunology
    Animals ; B7-H1 Antigen/immunology ; Cell Separation ; DNA, Viral/analysis ; Disease Progression ; Flow Cytometry ; Humans ; Lymphocyte Activation/immunology ; Macaca mulatta ; RNA, Viral/analysis ; Simian Acquired Immunodeficiency Syndrome/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Immune clearance of highly pathogenic SIV infection.
    Autorzy:
    Hansen SG; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon 97006, USA.
    Piatak M Jr
    Ventura AB
    Hughes CM
    Gilbride RM
    Ford JC
    Oswald K
    Shoemaker R
    Li Y
    Lewis MS
    Gilliam AN
    Xu G
    Whizin N
    Burwitz BJ
    Planer SL
    Turner JM
    Legasse AW
    Axthelm MK
    Nelson JA
    Früh K
    Sacha JB
    Estes JD
    Keele BF
    Edlefsen PT
    Lifson JD
    Picker LJ
    Pokaż więcej
    Źródło:
    Nature [Nature] 2013 Oct 03; Vol. 502 (7469), pp. 100-4. Date of Electronic Publication: 2013 Sep 11.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    SAIDS Vaccines/*immunology
    Simian Acquired Immunodeficiency Syndrome/*prevention & control
    Simian Immunodeficiency Virus/*immunology
    Animals ; Cytomegalovirus/genetics ; Cytomegalovirus/immunology ; Female ; Macaca mulatta ; Male ; Molecular Sequence Data ; Simian Acquired Immunodeficiency Syndrome/virology ; Time Factors ; Vaccines, Attenuated/immunology ; Viral Load ; Virus Replication/physiology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.
    Autorzy:
    Hansen SG; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
    Sacha JB
    Hughes CM
    Ford JC
    Burwitz BJ
    Scholz I
    Gilbride RM
    Lewis MS
    Gilliam AN
    Ventura AB
    Malouli D
    Xu G
    Richards R
    Whizin N
    Reed JS
    Hammond KB
    Fischer M
    Turner JM
    Legasse AW
    Axthelm MK
    Edlefsen PT
    Nelson JA
    Lifson JD
    Früh K
    Picker LJ
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2013 May 24; Vol. 340 (6135), pp. 1237874.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
    MeSH Terms:
    CD8-Positive T-Lymphocytes/*immunology
    Cytomegalovirus/*immunology
    Epitopes, T-Lymphocyte/*immunology
    Genetic Vectors/*immunology
    SAIDS Vaccines/*immunology
    Animals ; Cytokines/immunology ; Cytomegalovirus/genetics ; Female ; Genetic Vectors/genetics ; Histocompatibility Antigens Class II/immunology ; Humans ; Macaca mulatta ; Male ; Membrane Glycoproteins/genetics ; SAIDS Vaccines/administration & dosage ; Viral Envelope Proteins/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.
    Autorzy:
    Hansen SG; Vaccine and Gene Therapy Institute, Department of Molecular Microbiology, Oregon Health & Science University, Beaverton, Oregon 97006, USA.
    Ford JC
    Lewis MS
    Ventura AB
    Hughes CM
    Coyne-Johnson L
    Whizin N
    Oswald K
    Shoemaker R
    Swanson T
    Legasse AW
    Chiuchiolo MJ
    Parks CL
    Axthelm MK
    Nelson JA
    Jarvis MA
    Piatak M Jr
    Lifson JD
    Picker LJ
    Pokaż więcej
    Źródło:
    Nature [Nature] 2011 May 26; Vol. 473 (7348), pp. 523-7. Date of Electronic Publication: 2011 May 11.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Immunologic Memory/*immunology
    SAIDS Vaccines/*immunology
    Simian Acquired Immunodeficiency Syndrome/*immunology
    Simian Acquired Immunodeficiency Syndrome/*prevention & control
    Simian Immunodeficiency Virus/*immunology
    Simian Immunodeficiency Virus/*pathogenicity
    T-Lymphocytes/*immunology
    AIDS Vaccines/immunology ; Animals ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Cytomegalovirus/genetics ; DNA, Viral/analysis ; Genetic Vectors/genetics ; Immunity, Mucosal/immunology ; Macaca mulatta/blood ; Macaca mulatta/immunology ; Macaca mulatta/virology ; Male ; RNA, Viral/analysis ; SAIDS Vaccines/genetics ; Simian Acquired Immunodeficiency Syndrome/blood ; Simian Acquired Immunodeficiency Syndrome/virology ; Simian Immunodeficiency Virus/growth & development ; Simian Immunodeficiency Virus/isolation & purification ; Time Factors ; Vaccines, DNA/genetics ; Vaccines, DNA/immunology ; Viral Load ; Virus Replication
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.
    Autorzy:
    Hansen SG; Vaccine and Gene Therapy Institute, Department of Molecular Microbiology, and the Oregon National Primate Research Center, Oregon Health & Science University, 505 Northwest 185th Avenue, Beaverton, Oregon 97006, USA.
    Vieville C
    Whizin N
    Coyne-Johnson L
    Siess DC
    Drummond DD
    Legasse AW
    Axthelm MK
    Oswald K
    Trubey CM
    Piatak M Jr
    Lifson JD
    Nelson JA
    Jarvis MA
    Picker LJ
    Pokaż więcej
    Źródło:
    Nature medicine [Nat Med] 2009 Mar; Vol. 15 (3), pp. 293-9. Date of Electronic Publication: 2009 Feb 15.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Immunity, Mucosal*
    Immunologic Memory*
    CD4-Positive T-Lymphocytes/*immunology
    CD8-Positive T-Lymphocytes/*immunology
    Simian Immunodeficiency Virus/*immunology
    Animals ; Humans ; Macaca mulatta ; Male ; Viral Vaccines/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox.
    Autorzy:
    Hammarlund E; Vaccine and Gene Therapy Institute, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, Oregon 97006, USA.
    Lewis MW
    Carter SV
    Amanna I
    Hansen SG
    Strelow LI
    Wong SW
    Yoshihara P
    Hanifin JM
    Slifka MK
    Pokaż więcej
    Źródło:
    Nature medicine [Nat Med] 2005 Sep; Vol. 11 (9), pp. 1005-11. Date of Electronic Publication: 2005 Aug 07.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Technical Report
    MeSH Terms:
    Mpox (monkeypox)/*immunology
    Mpox (monkeypox)/*prevention & control
    Smallpox Vaccine/*immunology
    Animals ; Antibodies, Viral ; Cross Reactions ; Disease Outbreaks ; Disease Reservoirs ; Humans ; Mpox (monkeypox)/transmission ; Sciuridae/virology ; T-Lymphocytes/immunology ; Time Factors ; Wisconsin/epidemiology ; Zoonoses
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Duration of antiviral immunity after smallpox vaccination.
    Autorzy:
    Hammarlund E; Oregon Health & Science University Vaccine and Gene Therapy Institute, 505 NW 185th Avenue, Beaverton, Oregon 97006, USA.
    Lewis MW
    Hansen SG
    Strelow LI
    Nelson JA
    Sexton GJ
    Hanifin JM
    Slifka MK
    Pokaż więcej
    Źródło:
    Nature medicine [Nat Med] 2003 Sep; Vol. 9 (9), pp. 1131-7. Date of Electronic Publication: 2003 Aug 17.
    Typ publikacji:
    Journal Article; Research Support, U.S. Gov't, P.H.S.
    MeSH Terms:
    Immunologic Memory*
    Smallpox Vaccine/*immunology
    T-Lymphocytes/*immunology
    Adult ; Aged ; Antibody Formation ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Cross-Sectional Studies ; Female ; Half-Life ; Humans ; Immunization, Secondary ; Male ; Middle Aged ; Smallpox Vaccine/therapeutic use ; T-Lymphocytes/virology ; Time Factors ; Vaccinia virus/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-19 z 19

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies